This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. An example is the ability of a patient suffering from venous thrombosis to perform their own injections of heparin – an anticoagulant often packaged in a prefilled syringe.
The list includes providers of development services, biologics management supply chain solutions, clinical trial services, commercial and logistics services, as well as packaging, labelling and distributing services for biologics.
How will RFK Jr’s American dream for vaccines play out? Please check your inbox to download the Whitepaper. Please check your inbox to download the Whitepaper. Syngene’s expertise in the field is covered in this white paper. You will receive an email shortly. Syngene’s expertise in the field is covered in this white paper.
How will RFK Jr’s American dream for vaccines play out? Please check your inbox to download the Whitepaper. Please check your inbox to download the Whitepaper. You will receive an email shortly. You will receive an email shortly.
How will RFK Jr’s American dream for vaccines play out? Please check your inbox to download the Whitepaper. You will receive an email shortly. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications.
How will RFK Jr’s American dream for vaccines play out? Please check your inbox to download the Whitepaper. You will receive an email shortly. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications.
How will RFK Jr’s American dream for vaccines play out? Download our industry brief “Ensuring AI Compliance in Life Sciences: 5 Critical Requirements” for a clear path forward. Download our comprehensive industry brief to bridge the knowledge gap and implement AI with confidence. Download it now. 9, 2024.
How will RFK Jr’s American dream for vaccines play out? Download the free report today for data-driven insights into RWD. Please check your inbox to download the Report. Download the free report today for data-driven insights into RWD. Please check your inbox to download the Report.
The European Commission plans to launch its revised EU pharmaceutical package in Q1 2023 to ease drug shortages,” she says. Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds.
Please check your inbox to download the Whitepaper. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. You will receive an email shortly.
Forward-thinking suppliers, including packaging component providers, are also looking at how they can improve their processes through digital technologies. Tom Lenaerts is head of global process engineering for Datwyler, a leading supplier of parenteral packaging components such as stoppers and plungers. By Datwyler. United Kingdom.
Please check your inbox to download the Whitepaper. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. You will receive an email shortly.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. You will receive an email shortly.
According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.
Based on the individual contract, these CMOs manufacture small molecules or biological active pharmaceutical ingredients (APIs), as well as packaging material, and are charged with other related functions. Sharp Packaging Services is producing the solid dose of the drug and packaging it.
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus.
PM: Lyophilization is widely used in the pharmaceutical and biotech industry for small molecule drug products, vaccines, antibodies, and other biological material. That would not allow sufficient time to manufacture, package and distribute before half of the content was degraded. Please check your email to download the eBook.
The past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic, updates in regulations including the EU MDR and FDA guidance on bridging studies, and increasing industry acceptance of connectivity to aid the user experience. Secondary packagers.
The COVID-19 pandemic and the resulting demand that it put on the pharmaceutical industry to supply vaccines, highlighted how the supply chain has several potential points of failure, making it much harder to control and predict.
The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData.
Personally, I haven't seen this much attention in awhile about pharmacy since PillPack made strip-packaging of medications mainstream three-years ago, and am quite eager to see if this is really going to change the current paradigm of pharmacy services. Download Image. Each has pros and cons of services. after seeing a doctor visit.
Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity. The process eliminates the disadvantages of conventional drying methods or freezing.
At the start of 2022 alone, BenevolentAI partnered with AstraZeneca and Exscientia joined forces with Sanofi in deals designed to combine the efficiency-maximising power of AI-driven start-ups with the scale and reach of vaccine producing conglomerates. Download the whitepaper on this page to find out more. what it means for you.
4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™
Preparing for the impact of EU GMP Annex 1 on primary packaging Niamh Bissett and Dr Ana Kuschel West Pharmaceutical Services, Inc. Login or create an account to download your copy of our Issue now! The post <em>European Pharmaceutical Review </em> Issue 4 2024 appeared first on European Pharmaceutical Review.
All these challenges tend to lead to high costs for therapeutics and vaccines leveraging nanoscale drug delivery systems. The improved targeting capability of nanoscale delivery systems also leads to improved activation of immune cells in cancer vaccines. & Tech. 86, 104724. link] org/10.1016/j.jddst.2023.104724
Unlike vaccines, the agency leaders see the modality as a path to prevent and cure disease – aligning with the current administration’s wider national health strategy. Please check your inbox to download the Whitepaper. You will receive an email shortly. Give your business an edge with our leading industry insights.
Please check your inbox to download the Whitepaper. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. You will receive an email shortly.
Optimising HEK-293 cell culture medium for Influenza production Cell-culture based vaccines are a valuable alternative to egg-produced vaccines. For AAV, three different serotypes were studied (AAV-2, AAV-5, and AAV-8) and a three-plasmid packaging system was used. For lentivirus, a four-plasmid packaging system was used.
Download PDF. 1 risk factor for progression to severe disease a No prior COVID-19 vaccine or infectionStandard of care treatment allowed but primary analysis population was limited to subjects who did NOT receive COVID-19 monoclonal antibodies COVID-19 related hospitalizations/death through day 28: 0.8% Author: Alyssa Lear, PharmD.
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older.
How will RFK Jr’s American dream for vaccines play out? Free Whitepaper Future-proofing parenteral packaging against nitrosamines The discovery of large quantities of nitrosamines in many drugs has led to a high number of product recalls in recent years. Please check your inbox to download the Whitepaper.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content